Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: NASDAQ:), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist candidate, in obesity, including results from a body composition analysis recently completed, at the American Diabetes Association’s (ADA) 84th Scientific Sessions.

We are pleased with the data presented at the ADA highlighting the impressive weight loss achieved with pemvidutide, with only 21.9% of weight loss attributable to mild complications, said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. The preservation of lean weight observed in this study was better than historically reported with diet and exercise programs and greater than what has been publicly reported with other incretin drugs for weight loss, where empty weight has been about 40% of total weight. The maintenance of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical activity. We believe that the degree of muscle preservation seen in the Phase 2 trial further adds to the distinction of pemvidutide in the treatment of obesity.

The trial enrolled 391 people with obesity, or at least one morbid obesity and who did not have diabetes. Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in combination with diet and exercise. A small group of subjects was examined in the body composition analysis.

At week 48, people receiving pemvidutide experienced weight loss of 10.3%, 11.2%, 15.6% and 2.2% at doses of 1.2 mg, 1.8 mg and 2.4 mg and placebo, respectively, with sustained weight loss seen at a dose of 2.4 mg at the end of treatment. A comprehensive analysis of body composition based on MRI included 50 subjects who received pemvidutide and showed that subjects in the pemvidutide groups had an average weight loss of 21.9% and 78.1% of weight loss caused by fat. In addition, pemvidutide caused a strong reduction in serum lipids and an improvement in blood pressure without imbalance in cardiac events, arrhythmias or a clinically meaningful increase in heart rate.

Obesity is a multifactorial disease, and patients will need a variety of treatments tailored to their specific needs and comorbidities, says Louis Aronne, MD, Director of the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine and Science. Altimmune Advisor. These latest findings are particularly exciting given that pemvidutide has shown not only significant weight loss but a remarkable ability to maintain lean body mass. With its favorable safety profile to date and the potential to promote meaningful improvement in some obesity-related conditions such as dyslipidemia and hypertension, pemvidutide may offer a very promising, long-term treatment option for a large segment of obese patients to be safely protected. and effectively manage body weight.

About Pemvidutide

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of GLP-1 and glucagon receptors is believed to mimic the synergistic effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also known to have direct effects on hepatic fat metabolism, which is believed to lead to a rapid decrease in liver fat levels and serum lipids. In clinical trials so far, pemvidutide once a week has shown compelling weight loss, strong reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The US¯FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH study.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing next-generation peptide-based therapies. The company develops pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Forward-Looking Statement

Any statements made in this press release regarding future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of milestones for our clinical products, and prospects for use, regulatory approval, sales or sell any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, when or if used in this press release, the words may, may, should, expect, believe, estimate, expect, intend, plan, predict and similar expressions and their variations, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that could cause actual results to differ materially from the results discussed in forward-looking statements or historical experience include risks and uncertainties, including related risks: delays in regulatory review, disruptions in production and sales of goods, access to clinical sites, registration. , adverse effects on health care systems and disruption of the global economy; reliability of research results related to human safety and potential adverse effects from the handling of the Company’s product; the Company’s ability to conduct clinical trials at anticipated times; and the success of future product development, including the success of future clinical trials. Additional information about the factors and risks that may affect the Company’s business, financial conditions and results of operations is contained in the Company’s filings with the US Securities and Exchange Commission, including under the heading Risk Factors in the Company’s most recent annual report on Form 10.-K and other filings with the SEC, available at www.sec.gov.

Follow @Altimmune, Inc LinkedIn
Follow @AltimmuneInc at Twitter

Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Source: Altimmune, Inc